Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome

Pier Luigi Zinzani, Letizia Gandolfi, Vittorio Stefoni, Stefano Fanti, Mariapaola Fina, Cinzia Pellegrini, Gian Carlo Montini, Enrico Derenzini, Alessandro Broccoli, Lisa Argnani, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

Background: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database. Patients and Methods: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan (90Y-IT). The median number of pretreatments was 3 (range, 1-9 pretreatments). A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease. According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma. Results: Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months. All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (≥ 3 previous treatments), and 2 had had autologous stem cell transplantation. Toxicity was primarily hematologic and mostly transient; no grade 4 extrahematologic toxicity was observed. Conclusion: This study confirms the safety and high efficacy of 90Y-IT RIT in heavily pretreated FL patients, with the possibility of having a subset of long-term responders.

Original languageEnglish
Pages (from-to)258-261
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number4
DOIs
Publication statusPublished - Aug 2010

Keywords

  • Follicular lymphoma
  • Non-Hodgkin lymphoma
  • Pretreated indolent lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome'. Together they form a unique fingerprint.

  • Cite this

    Zinzani, P. L., Gandolfi, L., Stefoni, V., Fanti, S., Fina, M., Pellegrini, C., Montini, G. C., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S., & Baccarani, M. (2010). Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome. Clinical Lymphoma, Myeloma and Leukemia, 10(4), 258-261. https://doi.org/10.3816/CLML.2010.n.054